Is Embecta (EMBC) overvalued or fairly valued?

MarketChacha shows Embecta's valuation in context — a trailing P/E of about 1.8, a forward P/E of about 1.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Embecta's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.21×) from reported figures — education, not a rating.

What is Embecta's revenue?

Embecta reported revenue of $1.1B for FY2025, with net profit of $95.4M, per official filings.

What is the share price of Embecta (EMBC)?

Embecta last traded at $3.27 (-3.1% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Embecta

EMBC · NYSE · Healthcare · United States

$3.27-3.1%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:27 PM

Snapshot

TickerEMBC

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees1,850

HeadquartersParsippany, United States

Market cap$193.7M

P/E (TTM)1.8

Volume544.58K

Websitewww.embecta.com

Filings tracked3

About Embecta

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Profile as reported by Yahoo Finance.

Who owns it

Insiders1.7%
Institutions98.3%
Public & other0.0%

456 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.15.45%
Yacktman Asset Management Lp6.19%
American Century Companies Inc5.80%
Vanguard Capital Management LLC4.32%
State Street Corporation4.29%
Deerfield Management Company, L.P4.27%
Jefferies Financial Group Inc.3.97%
Sio Capital Management, LLC3.11%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.21×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend6.3% → 8.8%

Margin has expanded by about 2.5 points — the business is getting more profitable.

Growth qualityrev -2% · PAT 16%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $283.6M · EPS 0.34

Est. earnings growth -31.5%

Next fiscal year

Rev $1.1B · EPS 1.74

Est. earnings growth +9.3%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$2.7752-wk range$15.55

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$193.7M

Day change

-3.1%

P/E (TTM)

1.8

Fwd P/E

1.9

Div yield

13.65%

Beta

0.81

Revenue (FY2025)

$1.1B

Net margin

8.8%

Revenue CAGR (2y)

-1.8%

Profit CAGR (2y)

+16.4%

EPS (FY2025)

1.62

Net profit (FY2025)

$95.4M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about EMBC

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2025	$1.1B	$95.4M	1.62	8.8%
FY2024	$1.1B	$78.3M	1.34	7.0%
FY2023	$1.1B	$70.4M	1.22	6.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$221.8M	$-4.1M	-0.07	-1.8%
2025Q4	$261.2M	$44.1M	0.74	16.9%
2025Q2	$295.5M	$45.5M	0.78	15.4%
2025Q1	$259.0M	$23.5M	0.40	9.1%
2024Q4	$261.9M	$0	0.00	0.0%
2024Q2	$272.5M	$14.7M	0.25	5.4%
2024Q1	$287.2M	$28.9M	0.50	10.1%
2023Q4	$277.3M	$20.1M	0.35	7.2%
2023Q2	$286.1M	$15.2M	0.26	5.3%
2023Q1	$277.1M	$14.0M	0.24	5.1%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Completion of acquisition/disposition, Reg FD disclosure, Exhibits
SEC5/15/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.